Casdin Capital, LLC Denali Therapeutics Inc. Transaction History
Casdin Capital, LLC
- $1.16 Billion
- Q2 2024
A detailed history of Casdin Capital, LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 1,300,000 shares of DNLI stock, worth $35.9 Million. This represents 2.6% of its overall portfolio holdings.
Number of Shares
1,300,000
Previous 1,300,000
-0.0%
Holding current value
$35.9 Million
Previous $30.2 Million
-0.0%
% of portfolio
2.6%
Previous 2.61%
Shares
13 transactions
Others Institutions Holding DNLI
# of Institutions
217Shares Held
115MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$380 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$364 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$312 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$271 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$197 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.7B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...